Drug firm Strides Arcolab said it has received the US health regulator’s approval to market injectable Clindamycin USP, used in the treatment of bacterial infections, in the American market.
The product will be available in three single-dose vial sizes and in pharmacy bulk packaging, Strides Arcolab said in a statement.
“The product is expected to be launched in early 2012,” it said, adding that the company received approval for its Clindamycin USP from the US Food and Drug Administration (USFDA).

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.